Dogwood Therapeutics, Inc.

Clinical/early-stage biotech — clinical-stage biotech micro-cap, funded.

Strengths

• Liquidity — current ratio 2.8 (38th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Going concernRisks Related to Our Financial Position and Need for Additional Capital ● Our recurring losses from operations raise substantial doubt that we will be able to continue as a going concern and our ind
• Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
• Buying back stockNet buyback — share count -32%/yr over 4y
• Notable holderHeld by 1 notable fund(s): GOLDMAN SACHS GROUP INC (as of 2026-03-31)
• New fund positionNotable fund(s) opened this quarter: GOLDMAN SACHS GROUP INC
• Trial readout soonUpcoming trial readout ~2026-07 — PHASE2 · Chemotherapy Induced Neuropathic Pain